{"extractions": [{"extraction_class": "financial_fact", "extraction_text": "Cash, cash equivalents and marketable securities balance as of March 31, 2024, was $184.2 million", "char_interval": {"start_pos": 11248, "end_pos": 11345}, "alignment_status": "match_exact", "extraction_index": 1, "group_index": 0, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "The extracted fact is a composite of 'Cash, cash equivalents and restricted cash' and 'Available-for-sale debt securities', for which no single combined concept exists in the catalog. The value matches the sum of these two concepts in the catalog for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "$229.8 million as of December 31, 2023", "char_interval": {"start_pos": 11359, "end_pos": 11397}, "alignment_status": "match_exact", "extraction_index": 2, "group_index": 1, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": null, "matched_period": "2024-01-01", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "The extracted fact is a composite of 'Cash, cash equivalents and restricted cash' and 'Available-for-sale debt securities', for which no single combined concept exists in the catalog. The value matches the sum of these two concepts in the catalog for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Total revenue was $9.1 million for the quarter ended March 31, 2024", "char_interval": {"start_pos": 11414, "end_pos": 11481}, "alignment_status": "match_exact", "extraction_index": 3, "group_index": 2, "description": null, "attributes": {"concept_top1": "us-gaap:Revenues", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total revenue' to 'us-gaap:Revenues' with an exact historical value match for the specified quarter."}}, {"extraction_class": "financial_fact", "extraction_text": "total revenue of $24.5 million for the quarter ended March 31, 2023", "char_interval": {"start_pos": 11495, "end_pos": 11562}, "alignment_status": "match_exact", "extraction_index": 4, "group_index": 3, "description": null, "attributes": {"concept_top1": "us-gaap:Revenues", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'total revenue' to 'us-gaap:Revenues' for the specified prior-year quarter."}}, {"extraction_class": "financial_fact", "extraction_text": "$15.0 million milestone received from Incyte in the quarter ended March 31, 2023", "char_interval": {"start_pos": 11673, "end_pos": 11753}, "alignment_status": "match_exact", "extraction_index": 1, "group_index": 0, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "matched_dimension": "srt:MajorCustomersAxis", "matched_member": "mgnx:IncyteCorporationMember", "confidence": 0.4, "reasoning": "The text refers to a specific 'milestone' revenue from a particular customer. While it contributes to overall revenue, there isn't a direct XBRL concept for 'milestone' in the catalog, making 'UNMATCHED' appropriate. 'us-gaap:Revenues' is the closest general concept."}}, {"extraction_class": "financial_fact", "extraction_text": "Research and development expenses were $46.0 million for the quarter ended March 31, 2024", "char_interval": {"start_pos": 11775, "end_pos": 11864}, "alignment_status": "match_exact", "extraction_index": 2, "group_index": 1, "description": null, "attributes": {"concept_top1": "us-gaap:ResearchAndDevelopmentExpense", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Research and development expenses' with the concept 'us-gaap:ResearchAndDevelopmentExpense' and the specified period. Historical values align."}}, {"extraction_class": "financial_fact", "extraction_text": "$45.9 million for the quarter ended March 31, 2023", "char_interval": {"start_pos": 11878, "end_pos": 11928}, "alignment_status": "match_exact", "extraction_index": 3, "group_index": 2, "description": null, "attributes": {"concept_top1": "us-gaap:ResearchAndDevelopmentExpense", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Implied 'Research and development expenses' for the specified prior period, matching 'us-gaap:ResearchAndDevelopmentExpense'."}}, {"extraction_class": "financial_fact", "extraction_text": "Selling, general and administrative expenses were $14.7 million for the quarter ended March 31, 2024", "char_interval": {"start_pos": 11951, "end_pos": 12051}, "alignment_status": "match_exact", "extraction_index": 4, "group_index": 3, "description": null, "attributes": {"concept_top1": "us-gaap:GeneralAndAdministrativeExpense", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Selling, general and administrative expenses' with the concept 'us-gaap:GeneralAndAdministrativeExpense' and the specified period. Historical values align."}}, {"extraction_class": "financial_fact", "extraction_text": "$13.5 million for the quarter ended March 31, 2023", "char_interval": {"start_pos": 12065, "end_pos": 12115}, "alignment_status": "match_exact", "extraction_index": 5, "group_index": 4, "description": null, "attributes": {"concept_top1": "us-gaap:GeneralAndAdministrativeExpense", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Implied 'Selling, general and administrative expenses' for the specified prior period, matching 'us-gaap:GeneralAndAdministrativeExpense'."}}, {"extraction_class": "financial_fact", "extraction_text": "Net loss was $52.2 million for the quarter ended March 31, 2024", "char_interval": {"start_pos": 12243, "end_pos": 12306}, "alignment_status": "match_exact", "extraction_index": 6, "group_index": 5, "description": null, "attributes": {"concept_top1": "us-gaap:NetIncomeLoss", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Net loss' with the concept 'us-gaap:NetIncomeLoss' and the specified period. Historical values align."}}, {"extraction_class": "financial_fact", "extraction_text": "net loss of $38.0 million for the quarter ended March 31, 2023", "char_interval": {"start_pos": 12320, "end_pos": 12382}, "alignment_status": "match_exact", "extraction_index": 7, "group_index": 6, "description": null, "attributes": {"concept_top1": "us-gaap:NetIncomeLoss", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'net loss' with the concept 'us-gaap:NetIncomeLoss' and the specified period."}}, {"extraction_class": "financial_fact", "extraction_text": "Shares of common stock outstanding as of March 31, 2024 were 62,560,502", "char_interval": {"start_pos": 12410, "end_pos": 12481}, "alignment_status": "match_exact", "extraction_index": 8, "group_index": 7, "description": null, "attributes": {"concept_top1": "us-gaap:CommonStockSharesOutstanding", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "shares", "confidence": 0.95, "reasoning": "Direct match for 'Shares of common stock outstanding' with 'us-gaap:CommonStockSharesOutstanding'. The period 'as of March 31, 2024' maps to the instant '2024-04-01' in XBRL."}}, {"extraction_class": "financial_fact", "extraction_text": "cash, cash equivalents and marketable securities balance of $184.2 million as of March 31, 2024", "char_interval": {"start_pos": 12544, "end_pos": 12639}, "alignment_status": "match_exact", "extraction_index": 9, "group_index": 8, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.35, "reasoning": "The text describes a combined balance of 'cash, cash equivalents and marketable securities'. While components exist (e.g., 'us-gaap:CashAndCashEquivalentsAtCarryingValue', 'us-gaap:AvailableForSaleSecuritiesDebtSecurities'), there is no single XBRL concept in the catalog that represents this specific aggregate."}}, {"extraction_class": "financial_fact", "extraction_text": "Cash, cash equivalents and marketable securities $ 184,237", "char_interval": {"start_pos": 13836, "end_pos": 13894}, "alignment_status": "match_exact", "extraction_index": 1, "group_index": 0, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.3, "reasoning": "The fact represents a combination of cash, cash equivalents, and marketable securities, for which there is no single direct XBRL concept in the catalog. It appears to be a sum of us-gaap:CashAndCashEquivalentsAtCarryingValue and us-gaap:Investments."}}, {"extraction_class": "financial_fact", "extraction_text": "Cash, cash equivalents and marketable securities $ 229,805", "char_interval": {"start_pos": 13836, "end_pos": 13904}, "alignment_status": "match_fuzzy", "extraction_index": 2, "group_index": 1, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": null, "matched_period": "2024-01-01", "matched_unit": "iso4217:USD", "confidence": 0.3, "reasoning": "The fact represents a combination of cash, cash equivalents, and marketable securities, for which there is no single direct XBRL concept in the catalog. It appears to be a sum of us-gaap:CashAndCashEquivalentsAtCarryingValue and us-gaap:Investments."}}, {"extraction_class": "financial_fact", "extraction_text": "Total assets 248,285", "char_interval": {"start_pos": 13905, "end_pos": 13925}, "alignment_status": "match_exact", "extraction_index": 3, "group_index": 2, "description": null, "attributes": {"concept_top1": "us-gaap:Assets", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total assets' with `us-gaap:Assets` and value aligns with historical data for the closest period."}}, {"extraction_class": "financial_fact", "extraction_text": "Total assets 298,418", "char_interval": {"start_pos": 13905, "end_pos": 13933}, "alignment_status": "match_fuzzy", "extraction_index": 4, "group_index": 3, "description": null, "attributes": {"concept_top1": "us-gaap:Assets", "concept_top2": null, "matched_period": "2024-01-01", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total assets' with `us-gaap:Assets` and value aligns with historical data for the closest period."}}, {"extraction_class": "financial_fact", "extraction_text": "Deferred revenue 79,019", "char_interval": {"start_pos": 13934, "end_pos": 13957}, "alignment_status": "match_exact", "extraction_index": 5, "group_index": 4, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:ContractWithCustomerLiabilityCurrent", "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "The fact represents total deferred revenue, which is a sum of current and noncurrent contract liabilities. No single concept in the catalog represents this total."}}, {"extraction_class": "financial_fact", "extraction_text": "Deferred revenue 80,894", "char_interval": {"start_pos": 13934, "end_pos": 13964}, "alignment_status": "match_fuzzy", "extraction_index": 6, "group_index": 5, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:DeferredRevenueCurrent", "matched_period": "2024-01-01", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "The fact represents total deferred revenue, which is a sum of current and noncurrent deferred revenue. No single concept in the catalog represents this total."}}, {"extraction_class": "financial_fact", "extraction_text": "Total stockholders' equity 106,154", "char_interval": {"start_pos": 13965, "end_pos": 13999}, "alignment_status": "match_exact", "extraction_index": 7, "group_index": 6, "description": null, "attributes": {"concept_top1": "us-gaap:StockholdersEquity", "concept_top2": null, "matched_period": "2024-04-01", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total stockholders' equity' with `us-gaap:StockholdersEquity` and value aligns with historical data for the closest period."}}, {"extraction_class": "financial_fact", "extraction_text": "Total stockholders' equity 152,613", "char_interval": {"start_pos": 13965, "end_pos": 14007}, "alignment_status": "match_fuzzy", "extraction_index": 8, "group_index": 7, "description": null, "attributes": {"concept_top1": "us-gaap:StockholdersEquity", "concept_top2": null, "matched_period": "2024-01-01", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total stockholders' equity' with `us-gaap:StockholdersEquity` and value aligns with historical data for the closest period."}}, {"extraction_class": "financial_fact", "extraction_text": "Revenues: Collaborative and other agreements $ 1,449", "char_interval": {"start_pos": 14194, "end_pos": 14246}, "alignment_status": "match_exact", "extraction_index": 9, "group_index": 8, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Collaborative and other agreements') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Revenues: Collaborative and other agreements $ 16,686", "char_interval": {"start_pos": 14194, "end_pos": 14255}, "alignment_status": "match_fuzzy", "extraction_index": 10, "group_index": 9, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Collaborative and other agreements') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Product sales, net 4,861", "char_interval": {"start_pos": 14256, "end_pos": 14280}, "alignment_status": "match_exact", "extraction_index": 11, "group_index": 10, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Product sales, net') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Product sales, net 3,490", "char_interval": {"start_pos": 14256, "end_pos": 14286}, "alignment_status": "match_fuzzy", "extraction_index": 12, "group_index": 11, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Product sales, net') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Contract manufacturing 2,276", "char_interval": {"start_pos": 14287, "end_pos": 14315}, "alignment_status": "match_exact", "extraction_index": 13, "group_index": 12, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Contract manufacturing') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Contract manufacturing 3,615", "char_interval": {"start_pos": 14287, "end_pos": 14321}, "alignment_status": "match_fuzzy", "extraction_index": 14, "group_index": 13, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Contract manufacturing') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Royalty revenue 160", "char_interval": {"start_pos": 14322, "end_pos": 14341}, "alignment_status": "match_exact", "extraction_index": 15, "group_index": 14, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Royalty revenue') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Royalty revenue 422", "char_interval": {"start_pos": 14322, "end_pos": 14345}, "alignment_status": "match_fuzzy", "extraction_index": 16, "group_index": 15, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Royalty revenue') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Government agreements 358", "char_interval": {"start_pos": 14346, "end_pos": 14371}, "alignment_status": "match_exact", "extraction_index": 17, "group_index": 16, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Government agreements') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Government agreements 283", "char_interval": {"start_pos": 14346, "end_pos": 14375}, "alignment_status": "match_fuzzy", "extraction_index": 18, "group_index": 17, "description": null, "attributes": {"concept_top1": "UNMATCHED", "concept_top2": "us-gaap:Revenues", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.4, "reasoning": "This is a specific component of revenue ('Government agreements') for which no direct XBRL concept exists in the catalog. It is a sub-category of total revenues."}}, {"extraction_class": "financial_fact", "extraction_text": "Total revenues 9,104", "char_interval": {"start_pos": 14376, "end_pos": 14396}, "alignment_status": "match_exact", "extraction_index": 19, "group_index": 18, "description": null, "attributes": {"concept_top1": "us-gaap:Revenues", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total revenues' with `us-gaap:Revenues` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Total revenues 24,496", "char_interval": {"start_pos": 14376, "end_pos": 14403}, "alignment_status": "match_fuzzy", "extraction_index": 20, "group_index": 19, "description": null, "attributes": {"concept_top1": "us-gaap:Revenues", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total revenues' with `us-gaap:Revenues`."}}, {"extraction_class": "financial_fact", "extraction_text": "Cost of product sales 270", "char_interval": {"start_pos": 14424, "end_pos": 14449}, "alignment_status": "match_exact", "extraction_index": 21, "group_index": 20, "description": null, "attributes": {"concept_top1": "us-gaap:CostOfGoodsAndServicesSold", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Cost of product sales' with `us-gaap:CostOfGoodsAndServicesSold` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Cost of product sales 113", "char_interval": {"start_pos": 14424, "end_pos": 14453}, "alignment_status": "match_fuzzy", "extraction_index": 22, "group_index": 21, "description": null, "attributes": {"concept_top1": "us-gaap:CostOfGoodsAndServicesSold", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Cost of product sales' with `us-gaap:CostOfGoodsAndServicesSold`."}}, {"extraction_class": "financial_fact", "extraction_text": "Cost of manufacturing services 1,846", "char_interval": {"start_pos": 14454, "end_pos": 14490}, "alignment_status": "match_exact", "extraction_index": 23, "group_index": 22, "description": null, "attributes": {"concept_top1": "mgnx:CostOfManufacturingServices", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Cost of manufacturing services' with `mgnx:CostOfManufacturingServices` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Cost of manufacturing services 3,410", "char_interval": {"start_pos": 14454, "end_pos": 14496}, "alignment_status": "match_fuzzy", "extraction_index": 24, "group_index": 23, "description": null, "attributes": {"concept_top1": "mgnx:CostOfManufacturingServices", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Cost of manufacturing services' with `mgnx:CostOfManufacturingServices`."}}, {"extraction_class": "financial_fact", "extraction_text": "Research and development 46,029", "char_interval": {"start_pos": 14497, "end_pos": 14528}, "alignment_status": "match_exact", "extraction_index": 25, "group_index": 24, "description": null, "attributes": {"concept_top1": "us-gaap:ResearchAndDevelopmentExpense", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Research and development' with `us-gaap:ResearchAndDevelopmentExpense` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Research and development 45,872", "char_interval": {"start_pos": 14497, "end_pos": 14535}, "alignment_status": "match_fuzzy", "extraction_index": 26, "group_index": 25, "description": null, "attributes": {"concept_top1": "us-gaap:ResearchAndDevelopmentExpense", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Research and development' with `us-gaap:ResearchAndDevelopmentExpense`."}}, {"extraction_class": "financial_fact", "extraction_text": "Selling, general and administrative 14,709", "char_interval": {"start_pos": 14536, "end_pos": 14578}, "alignment_status": "match_exact", "extraction_index": 27, "group_index": 26, "description": null, "attributes": {"concept_top1": "us-gaap:GeneralAndAdministrativeExpense", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Selling, general and administrative' with `us-gaap:GeneralAndAdministrativeExpense` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Selling, general and administrative 13,527", "char_interval": {"start_pos": 14536, "end_pos": 14585}, "alignment_status": "match_fuzzy", "extraction_index": 28, "group_index": 27, "description": null, "attributes": {"concept_top1": "us-gaap:GeneralAndAdministrativeExpense", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Selling, general and administrative' with `us-gaap:GeneralAndAdministrativeExpense`."}}, {"extraction_class": "financial_fact", "extraction_text": "Total costs and expenses 62,854", "char_interval": {"start_pos": 14586, "end_pos": 14617}, "alignment_status": "match_exact", "extraction_index": 29, "group_index": 28, "description": null, "attributes": {"concept_top1": "us-gaap:CostsAndExpenses", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total costs and expenses' with `us-gaap:CostsAndExpenses` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Total costs and expenses 62,922", "char_interval": {"start_pos": 14586, "end_pos": 14624}, "alignment_status": "match_fuzzy", "extraction_index": 30, "group_index": 29, "description": null, "attributes": {"concept_top1": "us-gaap:CostsAndExpenses", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Total costs and expenses' with `us-gaap:CostsAndExpenses`."}}, {"extraction_class": "financial_fact", "extraction_text": "Loss from operations (53,750)", "char_interval": {"start_pos": 14625, "end_pos": 14654}, "alignment_status": "match_exact", "extraction_index": 31, "group_index": 30, "description": null, "attributes": {"concept_top1": "us-gaap:OperatingIncomeLoss", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Loss from operations' with `us-gaap:OperatingIncomeLoss` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Loss from operations (38,426)", "char_interval": {"start_pos": 14625, "end_pos": 14663}, "alignment_status": "match_fuzzy", "extraction_index": 32, "group_index": 31, "description": null, "attributes": {"concept_top1": "us-gaap:OperatingIncomeLoss", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Loss from operations' with `us-gaap:OperatingIncomeLoss`."}}, {"extraction_class": "financial_fact", "extraction_text": "Interest and other income 2,693", "char_interval": {"start_pos": 14664, "end_pos": 14695}, "alignment_status": "match_exact", "extraction_index": 33, "group_index": 32, "description": null, "attributes": {"concept_top1": "us-gaap:OtherNonoperatingIncome", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Interest and other income' with `us-gaap:OtherNonoperatingIncome` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Interest and other income 1,073", "char_interval": {"start_pos": 14664, "end_pos": 14701}, "alignment_status": "match_fuzzy", "extraction_index": 34, "group_index": 33, "description": null, "attributes": {"concept_top1": "us-gaap:OtherNonoperatingIncome", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Interest and other income' with `us-gaap:OtherNonoperatingIncome`."}}, {"extraction_class": "financial_fact", "extraction_text": "Interest and other expense (1,133)", "char_interval": {"start_pos": 14702, "end_pos": 14736}, "alignment_status": "match_exact", "extraction_index": 35, "group_index": 34, "description": null, "attributes": {"concept_top1": "us-gaap:InterestExpense", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.9, "reasoning": "'Interest and other expense' is a direct match for `us-gaap:InterestExpense`, and the value aligns with historical data."}}, {"extraction_class": "financial_fact", "extraction_text": "Interest and other expense (656)", "char_interval": {"start_pos": 14702, "end_pos": 14742}, "alignment_status": "match_fuzzy", "extraction_index": 36, "group_index": 35, "description": null, "attributes": {"concept_top1": "us-gaap:InterestExpense", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.9, "reasoning": "'Interest and other expense' is a direct match for `us-gaap:InterestExpense`."}}, {"extraction_class": "financial_fact", "extraction_text": "Net loss (52,190)", "char_interval": {"start_pos": 14743, "end_pos": 14760}, "alignment_status": "match_exact", "extraction_index": 37, "group_index": 36, "description": null, "attributes": {"concept_top1": "us-gaap:NetIncomeLoss", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Net loss' with `us-gaap:NetIncomeLoss` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Net loss (38,009)", "char_interval": {"start_pos": 14743, "end_pos": 14769}, "alignment_status": "match_fuzzy", "extraction_index": 38, "group_index": 37, "description": null, "attributes": {"concept_top1": "us-gaap:NetIncomeLoss", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Net loss' with `us-gaap:NetIncomeLoss`."}}, {"extraction_class": "financial_fact", "extraction_text": "Unrealized gain (loss) on investments (29)", "char_interval": {"start_pos": 14805, "end_pos": 14847}, "alignment_status": "match_exact", "extraction_index": 39, "group_index": 38, "description": null, "attributes": {"concept_top1": "us-gaap:UnrealizedGainLossOnInvestments", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Unrealized gain (loss) on investments' with `us-gaap:UnrealizedGainLossOnInvestments` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Unrealized gain (loss) on investments 13", "char_interval": {"start_pos": 14805, "end_pos": 14850}, "alignment_status": "match_fuzzy", "extraction_index": 40, "group_index": 39, "description": null, "attributes": {"concept_top1": "us-gaap:UnrealizedGainLossOnInvestments", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Unrealized gain (loss) on investments' with `us-gaap:UnrealizedGainLossOnInvestments`."}}, {"extraction_class": "financial_fact", "extraction_text": "Comprehensive loss $ (52,219)", "char_interval": {"start_pos": 14851, "end_pos": 14880}, "alignment_status": "match_exact", "extraction_index": 41, "group_index": 40, "description": null, "attributes": {"concept_top1": "us-gaap:ComprehensiveIncomeNetOfTax", "concept_top2": null, "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Comprehensive loss' with `us-gaap:ComprehensiveIncomeNetOfTax` and value aligns with historical data for the period."}}, {"extraction_class": "financial_fact", "extraction_text": "Comprehensive loss $ (37,996)", "char_interval": {"start_pos": 14851, "end_pos": 14891}, "alignment_status": "match_fuzzy", "extraction_index": 42, "group_index": 41, "description": null, "attributes": {"concept_top1": "us-gaap:ComprehensiveIncomeNetOfTax", "concept_top2": null, "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USD", "confidence": 0.95, "reasoning": "Direct match for 'Comprehensive loss' with `us-gaap:ComprehensiveIncomeNetOfTax`."}}, {"extraction_class": "financial_fact", "extraction_text": "Basic and diluted net loss per common share $ (0.84)", "char_interval": {"start_pos": 14892, "end_pos": 14944}, "alignment_status": "match_exact", "extraction_index": 43, "group_index": 42, "description": null, "attributes": {"concept_top1": "us-gaap:EarningsPerShareDiluted", "concept_top2": "us-gaap:EarningsPerShareBasic", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "iso4217:USDshares", "confidence": 0.85, "reasoning": "The fact states 'Basic and diluted net loss per common share', and the value matches both `us-gaap:EarningsPerShareDiluted` and `us-gaap:EarningsPerShareBasic` in history. Choosing diluted as primary."}}, {"extraction_class": "financial_fact", "extraction_text": "Basic and diluted net loss per common share $ (0.61)", "char_interval": {"start_pos": 14892, "end_pos": 14953}, "alignment_status": "match_fuzzy", "extraction_index": 44, "group_index": 43, "description": null, "attributes": {"concept_top1": "us-gaap:EarningsPerShareDiluted", "concept_top2": "us-gaap:EarningsPerShareBasic", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "iso4217:USDshares", "confidence": 0.85, "reasoning": "The fact states 'Basic and diluted net loss per common share', and the value matches both `us-gaap:EarningsPerShareDiluted` and `us-gaap:EarningsPerShareBasic`. Choosing diluted as primary."}}, {"extraction_class": "financial_fact", "extraction_text": "Basic and diluted weighted average common shares outstanding 62,290,538", "char_interval": {"start_pos": 14954, "end_pos": 15025}, "alignment_status": "match_exact", "extraction_index": 45, "group_index": 44, "description": null, "attributes": {"concept_top1": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "concept_top2": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "matched_period": "2024-01-01→2024-03-31", "matched_unit": "shares", "confidence": 0.85, "reasoning": "The fact states 'Basic and diluted weighted average common shares outstanding', and the value matches both `us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding` and `us-gaap:WeightedAverageNumberOfSharesOutstandingBasic` in history. Choosing diluted as primary."}}, {"extraction_class": "financial_fact", "extraction_text": "Basic and diluted weighted average common shares outstanding 61,809,817", "char_interval": {"start_pos": 14954, "end_pos": 15036}, "alignment_status": "match_fuzzy", "extraction_index": 46, "group_index": 45, "description": null, "attributes": {"concept_top1": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "concept_top2": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "matched_period": "2023-01-01→2023-03-31", "matched_unit": "shares", "confidence": 0.85, "reasoning": "The fact states 'Basic and diluted weighted average common shares outstanding', and the value matches both `us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding` and `us-gaap:WeightedAverageNumberOfSharesOutstandingBasic`. Choosing diluted as primary."}}], "text": "{\"EX-99.1\": {\"text\": \"Exhibit 99.1 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data \\u2022Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patients \\u2022Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, MD., May 9, 2024 (GLOBE NEWSWIRE) \\u2014 MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024. \\u201cWe are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-resistant prostate cancer,\\\" said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. \\u201cWe believe this interim data set helps validate our previously stated hypothesis that improved tolerability coupled with compelling biological activity could be achieved through dose reductions and a longer dosing interval. We believe vobra duo\\u2019s biological activity shown to date aligns well with the parameters we outlined at the outset of the study. Based on our evaluation of the interim data to date, we have initiated planning activities for a potential Phase 3 study that could commence next year. We anticipate sharing final safety, efficacy and durability data, including radiographic progression-free survival data, which is the primary endpoint of the study, in the second half of 2024. Furthermore, having preliminarily identified suitable vobra duo doses in mCRPC in the TAMARACK study, we have greater confidence in the molecule\\u2019s potential to help patients with a broad range of B7-H3-expressing cancers.\\u201d \\u201cThe interim safety and anti-tumor activity observed to date in the TAMARACK study look very promising for patients with metastatic castration-resistant prostate cancer,\\u201d said Johann DeBono, Regius Professor of Cancer Research and Professor in Experimental Cancer Medicine at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust. \\u201cWith the limited treatment options currently available to these patients, this novel ADC molecule could potentially become the first therapy targeting B7-H3 in patients with prostate cancer and would represent an important new treatment for this population.\\u201d Updates on Proprietary Investigational Programs Recent progress and anticipated events related to MacroGenics\\u2019 investigational product candidates are highlighted below. B7-H3-Directed Therapies \\u2022Vobramitamab duocarmazine (vobra duo) is an antibody-drug conjugate (ADC) that targets B7-H3, an antigen with broad expression across multiple solid tumors and a member of the B7 family of molecules involved in immune regulation. \\u2022MacroGenics completed enrollment of the TAMARACK Phase 2 study of vobra duo in November 2023. TAMARACK is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with one prior androgen receptor axis-targeted therapy (ARAT). Participants may have received up to one prior taxane-containing regimen, but no other chemotherapy agents. The TAMARACK study is designed to evaluate vobra duo at two different doses: 2.0 mg/kg or 2.7 mg/kg every four weeks (q4W). \\u2022A new presentation of TAMARACK interim data, consisting of updated safety and preliminary efficacy data, all based on a data cut-off date of April 12, 2024, is available under \\\"Events & Presentations\\\" in the Investor Relations section of MacroGenics\\u2019 website or directly via this link. Below is a high-level summary of this interim data, which is subject to further updates: Vobra Duo Vobra Duo 2.0 mg/kg q4W 2.7 mg/kg q4W Patients Enrolled n=91 n=90 PSA Reduction Summary: PSA Evaluable Patients n=82 n=71 Any PSA Reduction \\u226550% 41 (50.0%) 36 (50.7%) Confirmed PSA Reduction \\u226550% 36 (43.9%) 26 (36.6%) Tumor Response Summary: RECIST Evaluable Patients with Measurable Disease at Baseline n=45 n=32 Disease Control Rate (CR+PR+SD) 41 (91.1%) 28 (87.5%) Overall Response Rate (CR+PR, confirmed only) 8 (17.8%) 8 (25.0%) Overall Response Rate (CR+PR, including unconfirmed) 11 (24.4%) 14 (43.8%) Safety Summary: Safety Population n=90 n=86 Treatment-Emergent Adverse Events All Grade 89 (98.9%) 86 (100.0%) Treatment- Emergent Adverse Events Grade \\u22653 49 (54.4%) 44 (51.2%) TEAE Leading to Study Drug Discontinuation 10 (11.1%) 13 (15.1%) TEAE Leading to Study Drug Dose Reduction 39 (43.3%) 44 (51.2%) TEAE Leading to Study Drug Dose Interruption 38 (42.2%) 48 (55.8%) Five Most Common TEAE All Grade Asthenia (46.7%) Asthenia (58.1%) Nausea (35.6%) Decreased appetite (37.2%) Oedema peripheral (36.0%) Nausea (30.2%) Oedema peripheral (32.2%) Decreased appetite (28.9%) Fatigue (25.6%) Pleural effusion (29.1%) Pleural Effusions Grade 1=8.9% Grade 1=14.0% Grade 2=8.9% Grade 2=14.0% No Grade \\u2265 3 event Grade 3=1.2% Palmar-plantar Erythrodysaesthesia Syndrome Grade 1=11.1% Grade 1=12.8% Grade 2=4.4% Grade 2=9.3% No Grade \\u2265 3 event Grade 3=1.2% \\u2022The median number of cycles of vobra duo administered was five (range of 1-10). \\u2022A total of five events with fatal outcome occurred as follows: one Grade 5 event in the 2.0 mg/kg dosing cohort: acute myocardial infarction (considered unrelated to study drug by the investigator); three Grade 5 events in the 2.7 mg/kg dosing cohort: one cardiac arrest (considered unrelated to study drug by the investigator) and two events of pneumonitis. In addition, a patient in the 2.7 mg/kg dosing cohort had a Grade 3 pleural effusion that is recorded as having a fatal outcome. The latter three deaths are being investigated, as follow-up is incomplete on this ongoing trial. \\u2022Additional data is provided in the presentation on the Company\\u2019s website and as filed with the Securities and Exchange Commission. \\u2022Based on a current evaluation of this interim data, the Company is undertaking the initial steps necessary to prepare for the potential initiation of a Phase 3 study in mCRPC in 2025. The final decision to pursue such a Phase 3 study will be based on an analysis of the final data set, including rPFS, when available. \\u2022The Company intends to share final safety, efficacy, and durability data, including the primary endpoint of radiographic progression-free survival, from the TAMARACK trial in the second half of 2024. \\u2022MacroGenics plans to expand the TAMARACK study of vobra duo by enrolling patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN) and anal cancer. The Company expects to initiate dosing in these additional cohorts in mid-2024. \\u2022MacroGenics continues to enroll a Phase 1/2 dose escalation study of vobra duo in combination with lorigerlimab in patients with various advanced solid tumors. The Company anticipates commencing a dose expansion study of this combination in mCRPC and at least one additional indication in 2024. \\u2022MGC026 is a clinical B7-H3-targeting ADC that is site-specifically conjugated to exatecan, a topoisomerase I inhibitor payload developed by Synaffix (a Lonza company). With distinct mechanisms of action, vobra duo and MGC026 may address different cancers, tumor stages, or be used in combination with alternate agents \\u2014 or potentially with one another \\u2014 to enhance their clinical utility. A Phase 1 dose escalation study of MGC026 in patients with advanced solid tumors is ongoing. MGC026 preclinical data was presented recently at the American Association for Cancer Research (AACR) Annual Meeting. In preclinical studies, MGC026 was shown to have greater potency than B7-H3-directed antibodies conjugated to deruxtecan, or DXd, a topoisomerase-based payload utilized in other ADCs. In addition, the MGC026 payload has been shown to be less susceptible to multi-drug resistance (MDR) mechanisms than DXd and SN-38. \\u2022Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3. The HEAT study, an investigator-sponsored, randomized Phase 2 clinical trial being conducted by MacroGenics\\u2019 academic collaborators, is ongoing. This study is being conducted to evaluate the activity of neoadjuvant enoblituzumab given prior to radical prostatectomy in up to 219 men with high-risk localized prostate cancer. Lorigerlimab \\u2022Lorigerlimab is a bispecific, tetravalent PD-1 \\u00d7 CTLA-4 DART\\u00ae molecule. In addition to the ongoing study of lorigerlimab in combination with vobra duo mentioned above, MacroGenics is enrolling LORIKEET, a randomized Phase 2 study of lorigerlimab in combination with docetaxel vs. docetaxel alone in second-line, chemotherapy-na\\u00efve mCRPC patients. A total of 150 patients are planned to be treated in the 2:1 randomized study. The current trial design includes a primary study endpoint of radiographic progression-free survival (rPFS). The Company anticipates completing enrollment of the study in 2024 and providing a clinical update in the first half of 2025. Emerging ADC Pipeline \\u2022MGC028 is a preclinical ADC incorporating an ADAM9-targeting antibody and represents the second MacroGenics ADC molecule that incorporates Synaffix\\u2019s novel site-specific linker and topoisomerase I inhibitor-based cytotoxic payload. ADAM9 (a disintegrin and metalloprotease domain 9) is a member of the ADAM family of multifunctional type 1 transmembrane proteins that play a role in tumorigenesis and cancer progression and is overexpressed in multiple cancers, making it an attractive target for cancer treatment. The Company currently anticipates submitting an investigational new drug (IND) application for MGC028 by the end of 2024. MGC028 preclinical data was presented recently at the AACR Annual Meeting. In preclinical studies, MGC028 demonstrated specific antitumor activity in in vivo models representing gastric, lung, pancreatic, colorectal cancer, SCCHN and cholangiocarcinoma. In addition, in a non-human primate study, MGC028 was well tolerated at high dose levels, with mild, reversible side effects and no ocular toxicity, which is often a concern with tubulin-inhibitor-based ADCs. These promising preclinical results support the continued investigation of MGC028 as a therapeutic option for treating ADAM9-expressing solid cancers. Partnered Program \\u2022MGD024 is a next-generation, humanized CD123 \\u00d7 CD3 DART molecule designed to minimize cytokine-release syndrome, while maintaining anti-tumor cytolytic activity, and permitting intermittent dosing. MacroGenics continues to enroll patients in a Phase 1 dose-escalation study of MGD024 in patients with CD123-positive neoplasms, including acute myeloid leukemia and myelodysplastic syndromes. Under an October 2022 exclusive option and collaboration agreement, Gilead Sciences, Inc. has the option to license MGD024 at predefined decision points during the Phase 1 study. First Quarter 2024 Financial Results \\u2022Cash Position: Cash, cash equivalents and marketable securities balance as of March 31, 2024, was $184.2 million, compared to $229.8 million as of December 31, 2023. \\u2022Revenue: Total revenue was $9.1 million for the quarter ended March 31, 2024, compared to total revenue of $24.5 million for the quarter ended March 31, 2023. The decrease was primarily due to a decrease in revenue from collaborative and other agreements, including a $15.0 million milestone received from Incyte in the quarter ended March 31, 2023. \\u2022R&D Expenses: Research and development expenses were $46.0 million for the quarter ended March 31, 2024, compared to $45.9 million for the quarter ended March 31, 2023. \\u2022SG&A Expenses: Selling, general and administrative expenses were $14.7 million for the quarter ended March 31, 2024, compared to $13.5 million for the quarter ended March 31, 2023. The increase was primarily related to increased stock-based compensation expense and other professional fees. \\u2022Net Loss: Net loss was $52.2 million for the quarter ended March 31, 2024, compared to net loss of $38.0 million for the quarter ended March 31, 2023. \\u2022Shares Outstanding: Shares of common stock outstanding as of March 31, 2024 were 62,560,502. \\u2022Cash Runway Guidance: MacroGenics anticipates that its cash, cash equivalents and marketable securities balance of $184.2 million as of March 31, 2024, in addition to projected and anticipated future payments from partners and product revenues should extend its cash runway into 2026. The Company\\u2019s expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial, the Phase 2 LORIKEET study as well as MacroGenics\\u2019 other ongoing clinical and preclinical studies. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under \\\"Events & Presentations\\\" in the Investor Relations section of MacroGenics\\u2019 website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on MacroGenics\\u2019 website for 30 days following the call. MACROGENICS, INC. SELECTED CONSOLIDATED BALANCE SHEET DATA (Amounts in thousands) March 31, 2024 December 31, 2023 (unaudited) Cash, cash equivalents and marketable securities $ 184,237 $ 229,805 Total assets 248,285 298,418 Deferred revenue 79,019 80,894 Total stockholders' equity 106,154 152,613 MACROGENICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Amounts in thousands, except share and per share data) Three Months Ended March 31, 2024 2023 Revenues: Collaborative and other agreements $ 1,449 $ 16,686 Product sales, net 4,861 3,490 Contract manufacturing 2,276 3,615 Royalty revenue 160 422 Government agreements 358 283 Total revenues 9,104 24,496 Costs and expenses: Cost of product sales 270 113 Cost of manufacturing services 1,846 3,410 Research and development 46,029 45,872 Selling, general and administrative 14,709 13,527 Total costs and expenses 62,854 62,922 Loss from operations (53,750) (38,426) Interest and other income 2,693 1,073 Interest and other expense (1,133) (656) Net loss (52,190) (38,009) Other comprehensive income (loss): Unrealized gain (loss) on investments (29) 13 Comprehensive loss $ (52,219) $ (37,996) Basic and diluted net loss per common share $ (0.84) $ (0.61) Basic and diluted weighted average common shares outstanding 62,290,538 61,809,817 About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo, MARGENZA and DART are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (\\u201cCompany\\u201d), including statements about the Company\\u2019s strategy, future operations, clinical development of the Company\\u2019s therapeutic candidates, including initiation and enrollment in clinical trials, expected timing of results from clinical trials, discussions with regulatory agencies, commercial prospects of or product revenues from MARGENZA and the Company\\u2019s product candidates, if approved, manufacturing services revenue, milestone or opt-in payments from the Company\\u2019s collaborators, the Company\\u2019s anticipated milestones and future expectations and plans and prospects for the Company, as well as future global net sales of TZIELD and the Company\\u2019s ability to achieve the milestone payments set forth under the terms of the agreement with DRI (or its successors or assigns with respect to such agreement), and other statements containing the words \\u201csubject to\\u201d, \\\"believe\\\", \\u201canticipate\\u201d, \\u201cplan\\u201d, \\u201cexpect\\u201d, \\u201cintend\\u201d, \\u201cestimate\\u201d, \\u201cpotential,\\u201d \\u201cproject\\u201d, \\u201cmay\\u201d, \\u201cwill\\u201d, \\u201cshould\\u201d, \\u201cwould\\u201d, \\u201ccould\\u201d, \\u201ccan\\u201d, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate\\u2019s revenue, expenses and costs may not be as expected, risks relating to TZIELD, vobramitamab duocarmazine, lorigerlimab, ZYNYZ, MARGENZA or any other product candidate\\u2019s market acceptance, competition, reimbursement and regulatory actions; future data updates, especially with respect to vobramitamab duocarmazine; our ability to provide manufacturing services to our customers; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations of expanding ongoing clinical trials; availability and timing of data from ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises such as the novel coronavirus (referred to as COVID-19 pandemic); and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. ### CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com\", \"url\": \"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/exhibit99-1earningspressre.htm\"}}", "document_id": "doc_4326fbde"}
